Which is the Preferred Regimen for Non-Severe <i>Clostridioides difficile</i> Infection in Korea, Vancomycin or Metronidazole?
Jieun Kim, Jinyeong Kim, Bongyoung Kim, Hyunjoo Pai
Abstract
strains have not been reported. This review article aims to compare the treatment outcomes and adverse effects of vancomycin and metronidazole and discuss the validity of the guidelines of various agencies, which restrict the use of metronidazole, for Korean patients. There are no substantial adverse effects of metronidazole, and its clinical outcomes against non-severe CDI are similar to those of vancomycin. Based on these findings, we recommend that the use of metronidazole for the treatment of non-severe CDI is still an appropriate option in Korea.
Topics & Concepts
MetronidazoleFidaxomicinMedicineVancomycinRegimenAdverse effectClostridioidesInternal medicineAntibioticsIntensive care medicineMicrobiologyBacteriaBiologyGeneticsStaphylococcus aureusClostridium difficile and Clostridium perfringens researchMicroscopic ColitisViral gastroenteritis research and epidemiology